Join the Federalist Society for a webinar on the ongoing legal challenges to the Biden-era Medicare Drug Price Negotiation Program, a component of the Inflation Reduction Act. Ashley Parrish, Partner at King & Spalding, will provide an analysis of the multi-faceted litigation. He will explore how pharmaceutical companies are arguing that the program prevents accountability by granting the government "unlimited, unreviewable, unchecked rulemaking authority" over drug prices, and that it compels speech by forcing participation in agreements that imply voluntary negotiation. Mr. Parrish will also examine recent appellate court rulings and forecast the program's future, including its implications for the broader healthcare landscape.

Featuring:

Ashley C. Parrish, Partner, King & Spalding, LLP